Abivax Statement on Short Seller Report

November 20, 2026

Abivax Statement on Short Seller Report

PARIS, France – November 20, 2026 – 10:30 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) ("Abivax," the "Company," "we" or "our"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today issued a statement regarding a report published by Scorpion Capital on November 20, 2026.

We are reviewing the Scorpion Capital report in detail and anticipate providing further updates regarding this matter. Based on Abivax's current review, it is clear that the report contains numerous factually inaccurate and misleading statements, assumptions, and conclusions, including those based on studies commissioned and funded by Scorpion Capital itself. We firmly stand behind the integrity of our clinical development program, including the results of our Phase 3 ABTECT trials and the strength of the clinical data generated to date, which will support Abivax's U.S. FDA NDA filing by the end of the year.

Notably, Scorpion Capital explicitly disclosed its short position in Abivax and its intention to begin covering a substantial portion of that position upon publication of its report, underscoring its direct financial interest in a decline in our share price. These direct financial incentives provide important context for evaluating the report.

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:
Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878

Media Contacts:
LifeSci Communications
Karissa Baltz, PhD
Associate Director
LSC_ABIVAX@lifescicomms.com

Longacre Square Partners
Abivax@longacresquare.com

Attachment

- 261120_Abivax_PR_Statement Short Seller Report